Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
about
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targetsThe RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation.Novel complex integrating mitochondria and the microtubular cytoskeleton with chromosome remodeling and tumor suppressor RASSF1 deduced by in silico homology analysis, interaction cloning in yeast, and colocalization in cultured cellsPutative tumor suppressor RASSF1 interactive protein and cell death inducer C19ORF5 is a DNA binding proteinThe tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complexThe RASSF1A tumor suppressor restrains anaphase-promoting complex/cyclosome activity during the G1/S phase transition to promote cell cycle progression in human epithelial cellsWNT7a induces E-cadherin in lung cancer cellsBeta-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletionThe tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2.The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell deathHYAL1 and HYAL2 inhibit tumour growth in vivo but not in vitroRegulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by RasDRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected]Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3BMolecular biology of lung cancer: clinical implicationsSurfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics? (Review)Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivoGenetic alteration and gene expression modulation during cancer progressionCharacteristic promoter hypermethylation signatures in male germ cell tumorsThe molecular basis of lung cancer: molecular abnormalities and therapeutic implicationsFrom Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung CancersThe pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lungTumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancersAberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell linesAberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancersRAS oncogenes: weaving a tumorigenic webRASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumorsCpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancerThe growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathwayHigh-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele lossChromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features.DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an updateA genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignanciesRASSF6 is a novel member of the RASSF family of tumor suppressorsDNA IR-Double Strand Breaks (DSBs) and cellular response via ATMFrequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.The growth and tumor suppressors NORE1A and RASSF1A are targets for calpain-mediated proteolysis.Microtubule segment stabilization by RASSF1A is required for proper microtubule dynamics and Golgi integrity.Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastomaThe Ras-association domain family (RASSF) members and their role in human tumourigenesis.
P2860
Q21245727-6C921E15-F4D6-4DFD-9D0B-09F8DF570163Q24297959-5F31ED1C-0D4A-4A1C-8D38-360977A34433Q24302341-77F8C7A7-A8EE-41FC-A664-02E56E8AA298Q24303018-E4FCD0D3-989D-4A24-89C2-0E6001EC67ACQ24306286-F60022AB-0846-4EDD-A9C6-452CBD1B12D6Q24312020-A9887F39-D336-482C-82FE-58E4DA11EEB6Q24317695-9D1A017A-6A34-4DBC-8B2F-911A5D34B676Q24322289-01D8BAAE-AA65-480F-BD1C-5DC680D35EAEQ24322848-AD5877AD-AD3C-4FFA-AE78-54A32FCA4DE6Q24336280-008AF069-CFAF-4839-BE80-064F663638E5Q24336517-CE0B1F77-FF08-4443-9BA7-7E4DDBC331E2Q24338128-ADC7548F-3F24-431D-8F84-C9585865CED1Q24339462-77A2D8B1-05F4-4B63-AA3D-CC7800EB412BQ24555083-94DCD470-CD53-44D6-BC3E-809022E7FFC4Q24610335-CCA8D863-DCC3-4D65-8C8B-D8BB1D01BE89Q24617128-280105B1-E673-4CEC-9838-4B2FA0DFCDF2Q24625463-96E16511-DF27-4D3F-B147-ED0B8E7583B0Q24798750-D97522C8-E3C6-4EEE-B5F1-8892D185813AQ24799928-1394483A-7E28-4389-9167-6F43D17C22F9Q24802445-B0C55FED-5500-4F0C-A904-F7A73062495BQ26771375-29828BBC-BD45-4FF1-84F9-B392C81B73FFQ28188823-70A72FB8-6E26-4BB9-A290-5E2D14EE2EABQ28206723-5AC3A8C9-D17E-434F-A749-D084C1728995Q28206870-D52BEC6F-DEAE-4279-AC53-7849371B7337Q28214439-969B5173-FFA6-41E0-A4D1-309917824B82Q28250360-5642495F-779E-4B47-8A9E-DC849A790AA4Q28258450-132DF61B-0644-4F10-9D2D-3EF712A40BC2Q28283044-B3BFE4E2-B510-4D51-84BB-0E4AC3100DE9Q28292458-060D0411-3852-4597-B4A0-21B58AB6C91DQ28343524-11D7F9BB-F07F-43F8-800F-FBD211231E99Q28360494-0EBB77B8-89B4-4CE9-A201-5948A7563C91Q28386334-3690764E-656F-48D2-BE13-943DACB71E2FQ28469084-57E4DB20-94D6-4016-84BE-010203B21224Q28509722-ED9AF9D3-4775-42F7-A5A2-F7C9841D23D7Q30225541-C6056EA1-7EE1-43B1-BDCE-CBD04423CD15Q30320562-EB4C2823-A500-4B22-85D6-7CA94CC4FAADQ30440607-64C957E9-9F6E-4A16-A9CF-5D07C7E25A6BQ30574008-54721BF5-17DB-44CC-8411-CC13F0675D55Q30781403-56B36BBF-BFCD-470A-845B-672D01A3C575Q31121564-C7F78886-E73B-44C2-A6D2-93AC09D3A4B4
P2860
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@ast
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@en
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@en-gb
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@nl
type
label
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@ast
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@en
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@en-gb
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@nl
prefLabel
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@ast
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@en
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@en-gb
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@nl
P2093
P2860
P3181
P356
P1476
Epigenetic inactivation of RAS ...... alignant phenotype suppression
@en
P2093
A F Gazdar
D G Burbee
E Zabarovsky
P2860
P3181
P356
10.1093/JNCI/93.9.691
P407
P577
2001-05-02T00:00:00Z